Sai Life Sciences Ltd
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
- Market Cap ₹ 17,742 Cr.
- Current Price ₹ 840
- High / Low ₹ 984 / 635
- Stock P/E 61.9
- Book Value ₹ 108
- Dividend Yield 0.00 %
- ROCE 14.0 %
- ROE 11.0 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is expected to give good quarter
Cons
- Stock is trading at 7.58 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 7.86% over last 3 years.
- Working capital days have increased from 37.8 days to 66.4 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE Allcap BSE 250 SmallCap Index
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,053 | |
| 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,509 | |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 544 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 26% |
| 6 | 18 | 27 | 28 | 27 | 29 | 35 | 44 | |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 56 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 149 |
| Profit before tax | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 383 |
| Tax % | 35% | 30% | 25% | 36% | 39% | 24% | 25% | |
| 73 | 76 | 61 | 6 | 10 | 83 | 170 | 286 | |
| EPS in Rs | 8.16 | 13.73 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 1,116% | 676% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 25% |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 229% |
| TTM: | 131% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 27% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 8% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,249 |
| 249 | 304 | 637 | 752 | 933 | 928 | 352 | 418 | |
| 247 | 312 | 318 | 527 | 358 | 359 | 665 | 644 | |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,332 |
| 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,622 | |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 115 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 |
| 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,592 | |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,332 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 129 | 116 | -36 | 105 | 219 | 263 | 314 | |
| -158 | -262 | -260 | -102 | -99 | -191 | -536 | |
| 268 | -4 | 296 | 72 | -201 | -95 | 301 | |
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 99 | 102 | 85 | 64 | 76 |
| Inventory Days | 86 | 79 | 127 | 179 | 121 | 72 | 93 |
| Days Payable | 207 | 258 | 230 | 279 | 180 | 113 | 253 |
| Cash Conversion Cycle | 1 | -43 | -4 | 2 | 25 | 22 | -83 |
| Working Capital Days | 55 | 24 | 62 | 42 | 36 | 12 | 66 |
| ROCE % | 13% | 9% | 3% | 6% | 11% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Jan - Jan 28, 2026: Sai Life Sciences and Mabtech to co-market EYRA immunology services at Sai’s Boston site.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
28 Jan - Q3FY26 un-audited results conference call on Feb 6, 2026 at 4:00 PM IST.
-
Board Meeting Intimation for Consideration And Approval Of Un-Audited Financial Results For The Third Quarter And Nine Months Ended December 31, 2025.
22 Jan - Board meeting 5 Feb 2026 to approve unaudited Q3/nine-month results; trading window closed from 01 Jan 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
12 Jan - RTA certificate under SEBI Regulation 74(5) submitted for quarter ended December 31, 2025.
-
Intimation Of Receipt Of Letter From BSE Dated 06 January 2026 And NSE Dated 07 January 2026.
7 Jan - BSE (06 Jan 2026) and NSE (07 Jan 2026) warning letters for missing SRC meeting FY2024-25.
Concalls
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Feb 2025TranscriptAI SummaryPPT REC
Business Overview:[1]
a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe.
b) It offers integrated services across the pharmaceutical lifecycle from discovery services to development and manufacturing of new chemical entities to global innovator pharmaceutical and biotechnology companies.
c) In FY24, company has completed
200+ discovery programmes and 40+ programmes have advanced to clinical
phases.
d) SLS has a fully integrated in-house
synthetic and medicinal chemistry, drug metabolism, biology, pharmacokinetics
and toxicology.
e) In terms of therapy, they have worked in oncology and other key therapy areas include central nervous system, inflammation and anti
virals.
f) SLS provides its services to 17 out of the top 20 global pharmaceutical companies and several biotechnology companies.